Esprit Ma1, Vijayveer Bonthapally2, Anita Chawla3, Patrick Lefebvre4, Ronan Swords5, Marie-Hélène Lafeuille6, Jonathan Fortier6, Bruno Emond6, Mei Sheng Duh7, Bruce J Dezube8. 1. Medivation, Inc, San Francisco, CA. 2. Sage Therapeutics, Cambridge, MA. 3. Analysis Group, Inc, Menlo Park, CA. 4. Groupe d'analyse, Ltée, Montreal, QC, Canada. Electronic address: Patrick.Lefebvre@analysisgroup.com. 5. Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. 6. Groupe d'analyse, Ltée, Montreal, QC, Canada. 7. Analysis Group, Inc, Boston, MA. 8. Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA.
Abstract
BACKGROUND: Many elderly patients with acute myeloid leukemia (AML) are considered ineligible for standard intensive induction therapy due to performance status and comorbidities. We analyzed treatment patterns and outcomes among elderly patients newly diagnosed with AML in the US community oncology setting. METHODS: A retrospective observational study was conducted using patient-level data from a network of US community oncology practices provided by Altos Solutions. Patients aged ≥ 60 years, diagnosed with AML between November 2005 and February 2014, with ≥ 1 recorded visit and ≥ 6 months between diagnosis and data cutoff, were included. Only patients who received active treatment or best supportive care (BSC) per National Comprehensive Cancer Network (NCCN) AML Guidelines were analyzed. RESULTS: Of 1139 patients meeting the inclusion criteria, 922 (median age 76 years) received NCCN-recommended treatments: standard induction (n = 5), low-intensity therapy (n = 425), BSC with hydroxyurea (HU) (n = 36), or BSC without HU (n = 455). For the low-intensity therapy cohort, median time from diagnosis to treatment initiation was 17 days; median duration of therapy was 5.1 months. Median overall survival (OS) from diagnosis in the low-intensity, BSC with HU, and BSC without HU groups was 12.3, 7.0, and 49.4 months, respectively. Median time to next therapy/death was 10.1 months in patients receiving low-intensity therapy. A higher proportion of patients receiving low-intensity therapy required transfusion or other supportive care versus those receiving BSC. CONCLUSIONS: As expected, OS in patients receiving low-intensity therapy or BSC with HU is poor for elderly patients with AML. Remarkably, intensive induction strategies are rarely used for older patients in community oncology practice.
BACKGROUND: Many elderly patients with acute myeloid leukemia (AML) are considered ineligible for standard intensive induction therapy due to performance status and comorbidities. We analyzed treatment patterns and outcomes among elderly patients newly diagnosed with AML in the US community oncology setting. METHODS: A retrospective observational study was conducted using patient-level data from a network of US community oncology practices provided by Altos Solutions. Patients aged ≥ 60 years, diagnosed with AML between November 2005 and February 2014, with ≥ 1 recorded visit and ≥ 6 months between diagnosis and data cutoff, were included. Only patients who received active treatment or best supportive care (BSC) per National Comprehensive Cancer Network (NCCN) AML Guidelines were analyzed. RESULTS: Of 1139 patients meeting the inclusion criteria, 922 (median age 76 years) received NCCN-recommended treatments: standard induction (n = 5), low-intensity therapy (n = 425), BSC with hydroxyurea (HU) (n = 36), or BSC without HU (n = 455). For the low-intensity therapy cohort, median time from diagnosis to treatment initiation was 17 days; median duration of therapy was 5.1 months. Median overall survival (OS) from diagnosis in the low-intensity, BSC with HU, and BSC without HU groups was 12.3, 7.0, and 49.4 months, respectively. Median time to next therapy/death was 10.1 months in patients receiving low-intensity therapy. A higher proportion of patients receiving low-intensity therapy required transfusion or other supportive care versus those receiving BSC. CONCLUSIONS: As expected, OS in patients receiving low-intensity therapy or BSC with HU is poor for elderly patients with AML. Remarkably, intensive induction strategies are rarely used for older patients in community oncology practice.
Authors: Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen Journal: Blood Adv Date: 2020-08-11
Authors: Andrew H Wei; Stephen A Strickland; Jing-Zhou Hou; Walter Fiedler; Tara L Lin; Roland B Walter; Anoop Enjeti; Ing Soo Tiong; Michael Savona; Sangmin Lee; Brenda Chyla; Relja Popovic; Ahmed Hamed Salem; Suresh Agarwal; Tu Xu; Kaffa M Fakouhi; Rod Humerickhouse; Wan-Jen Hong; John Hayslip; Gail J Roboz Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544
Authors: James D Griffin; Hongbo Yang; Yan Song; David Kinrich; Manasee V Shah; Cat N Bui Journal: Eur J Haematol Date: 2019-02-05 Impact factor: 2.997
Authors: Tamer A Othman; Matthew E Tenold; Benjamin N Moskoff; Tali Azenkot; Brian A Jonas Journal: Expert Rev Hematol Date: 2021-06-15 Impact factor: 2.819
Authors: Xiaomei Ma; David P Steensma; Bart L Scott; Pavel Kiselev; Mary M Sugrue; Arlene S Swern Journal: BMJ Open Date: 2018-07-23 Impact factor: 2.692
Authors: Alice S Mims; Jessica Kohlschmidt; Uma Borate; James S Blachly; Shelley Orwick; Ann-Kathrin Eisfeld; Dimitrios Papaioannou; Deedra Nicolet; Krzysztof Mrόzek; Eytan Stein; Bhavana Bhatnagar; Richard M Stone; Jonathan E Kolitz; Eunice S Wang; Bayard L Powell; Amy Burd; Ross L Levine; Brian J Druker; Clara D Bloomfield; John C Byrd Journal: J Hematol Oncol Date: 2021-06-23 Impact factor: 17.388